Julie Pilitsis

2 months ago | neurologylive.com | Julie Pilitsis |Isabella Ciccone

CommentaryVideoFebruary 13, 2025Author(s):,Fact checked by:The chair of neurosurgery at the University of Arizona talked about the newly approved infusion therapy that offers continuous medication delivery to improve both motor and non-motor symptoms in Parkinson disease.

2 months ago | neurologylive.com | Julie Pilitsis |Isabella Ciccone

Parkinson disease (PD) is characterized by progressive neurodegeneration of the substantia nigra, leading to striatal dopamine deficiency and motor symptoms. Although studies have shown the efficacy of dopamine replacement therapy, most patients eventually develop motor fluctuations that require treatment adjustment.1 Deep brain stimulation and continuous dopaminergic drug delivery offer effective options for managing persistent motor complications, though both are invasive.

2 months ago | drugtopics.com | Julie Pilitsis |Ashley Gallagher

Julie Pilitsis, MD, PhD, a neurosurgeon and expert in neuromodulation at Banner-University Medicine and chair of the department of neurosurgery at the University of Arizona College of Medicine-Tucson, focuses on the benefits of using apomorphine infusion to treat patients with moderate-to-severe Parkinson disease. She emphasizes how this treatment can help reduce the unpredictability and severe fluctuations in symptoms that often bother patients with Parkinson disease the most.

Apr 4, 2024 | medrxiv.org | Rahul Rajeev |Ayan Chatterjee |Julie Pilitsis |Sreya Sunil

SIENNA is patent pending in 63,465,719, an Artificial Intelligence System for Tumor Diagnostics of Clinical MRI Datasets. JLP, AM and AC are cofounders of the startup ITrakNeuro Inc. Dr. Pilitsis receives grant support from Medtronic, Boston Scientific, Abbott, NIH 2R01CA166379, NIH R01EB030324, and NIH U44NS115111. She is the medical advisor for Aim Medical Robotics and has stock equity.

Apr 11, 2023 | neurologylive.com | Julie Pilitsis

WATCH TIME: 4 minutesThe development of modern deep brain stimulation (DBS) technology began in 1947, with the introduction of an innovative stereotactic apparatus by 2 scientists who referred to it as stereoencephalotomy. Originally designed for the localization of ablative procedures, the approach significantly cut down mortality rate, and was further explored across other subspecialties. In 1975, Medtronic became the first company to trademark the term “DBS” for deep brain stimulation.